Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lopinavir

FDA-approved product (capsule, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Lopinavir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

Anti-infective classification
Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.

Repurposing investigation

Lopinavir reaches ≥40% AI-predicted activity against MRSA and M. tuberculosis, but no WHO ATC code or FDA pharmacologic class says whether it is already an antimicrobial. It needs review, so it is not counted among the repurposing candidates.

AI-predicted activity

AI prediction · nothing measured
  • MRSA40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lopinavir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lopinavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

    NCT00708162 · start 2008-07

    Registered record
    Registry ID
    NCT00708162
    Conditions
    HIV Infection
    Interventions
    Elvitegravir; Raltegravir; EVG placebo; RAL placebo; Background regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-07
    Completion
    2015-04
    Enrolment
    724

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionElvitegravir; Raltegravir; EVG placebo; RAL placebo +1 more
    PhasePhase 3
    Registry statusCompleted

  • Raltegravir Insulin Sensitivity Study

    NCT00531999 · start 2007-10

    Registered record
    Registry ID
    NCT00531999
    Conditions
    HIV Infections
    Interventions
    Raltegravir then lopinavir/ritonavir; Lopinavir/ritonavir then raltegravir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-10
    Completion
    2008-08
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionRaltegravir then lopinavir/ritonavir; Lopinavir/ritonavir then raltegravir
    PhasePhase 1
    Registry statusCompleted

  • Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy

    NCT00437684 · start 2007-02

    Registered record
    Registry ID
    NCT00437684
    Conditions
    HIV Infections; Hepatitis C
    Interventions
    LPV/r; PEG-IFNa 2a; Ribavirin; NUCS
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2007-02
    Completion
    2010-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Hepatitis C
    InterventionLPV/r; PEG-IFNa 2a; Ribavirin; NUCS
    PhasePhase 3
    Registry statusUnknown

  • Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV

    NCT00270296 · start 2006-06

    Registered record
    Registry ID
    NCT00270296
    Conditions
    HIV Infections
    Interventions
    Trizivir; Lamivudine/Zidovudine; Lopinavir/Ritonavir; Nevirapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-06
    Completion
    2010-09
    Enrolment
    730

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTrizivir; Lamivudine/Zidovudine; Lopinavir/Ritonavir; Nevirapine
    PhasePhase 2
    Registry statusCompleted

  • Metabolic Effects of Switching Kaletra to Boosted Reyataz

    NCT00413153 · start 2006-05

    Registered record
    Registry ID
    NCT00413153
    Conditions
    HIV Infections
    Interventions
    atazanavir/ritonavir; lopinavir/ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-05
    Completion
    2008-12
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionatazanavir/ritonavir; lopinavir/ritonavir
    PhaseNot applicable
    Registry statusCompleted

  • Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study

    NCT00344487 · start 2005-12

    Registered record
    Registry ID
    NCT00344487
    Conditions
    HIV
    Interventions
    Lopinavir/Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2005-12
    Completion
    2009-09
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionLopinavir/Ritonavir
    PhaseNot applicable
    Registry statusTerminated

  • Induction-maintenance of Lopinavir/r in HIV-infected Subjects

    NCT00159224 · start 2005-04

    Registered record
    Registry ID
    NCT00159224
    Conditions
    HIV Infections
    Interventions
    Lopinavir/ritonavir simplification strategy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-04
    Completion
    2009-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionLopinavir/ritonavir simplification strategy
    PhasePhase 4
    Registry statusCompleted

  • Study to Evaluate the Effectiveness of ABC+3TC +EFV in Once-Daily Regimens Versus KLT in Twice-Daily Regimens in Naive HIV Patients

    NCT00318123 · start 2004-04

    Registered record
    Registry ID
    NCT00318123
    Conditions
    HIV Infections
    Interventions
    Kivexa
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-04
    Completion
    2007-04
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionKivexa
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients

    NCT00648999 · start 2003-11

    Registered record
    Registry ID
    NCT00648999
    Conditions
    Human Immunodeficiency Virus
    Interventions
    lopinavir/ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-11
    Completion
    2006-12
    Enrolment
    207

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus
    Interventionlopinavir/ritonavir
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

    NCT00042289 · start 2003-06-09

    Registered record
    Registry ID
    NCT00042289
    Conditions
    HIV Infections
    Interventions
    atazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3; elvitegravir/cobicistat; dolutegravir; tenofovir alafenamide fumarate (TAF); TAF w/cobicistat; TAF w/cobicistat or ritonavir; efavirenz; darunavir/cobicistat; lopinavir/ritonavir dosage #1; atazanavir/ritonavir/tenofovir dosage #1; rifampicin; ethambutol; isoniazid; pyrazinamide; kanamycin; amikacin; capreomycin; moxifloxacin; levoflaxacin; ofloxacin; ethionamide/prothionamide; terizidone/cycloserine; para-aminosalicylic acid (PAS); high dose INH; bedaquiline; clofazamine; delamanid; linezolid; pretomanid; ethinyl estradiol; etonogestrel implant; nevirapine; amprenavir; abacavir; lopinavir/ritonavir dosage #2; indinavir/ritonavir dosage #1; fosamprenavir/ritonavir; lopinavir/ritonavir dosage #3; atazanavir/ritonavir dosage #1; didanosine delayed release (Videx® EC); emtricitabine; tenofovir; nelfinavir dosage #1; tipranavir/ritonavir; lopinavir/ritonavir dosage #4; ralteg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2003-06-09
    Completion
    2020-09-30
    Enrolment
    1,578

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionatazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3 +45 more
    PhaseNot recorded
    Registry statusCompleted

  • Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score

    NCT00234975 · start 2002-10

    Registered record
    Registry ID
    NCT00234975
    Conditions
    HIV Infection
    Interventions
    Lopinavir/Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-10
    Completion
    2008-01
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionLopinavir/Ritonavir
    PhasePhase 4
    Registry statusCompleted

  • Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

    NCT01003990 · start 2002-10

    Registered record
    Registry ID
    NCT01003990
    Conditions
    HIV
    Interventions
    Atazanavir; Atazanavir/Ritonavir; Tenofovir/Emtricitabine; Lopinavir/ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-10
    Completion
    2016-02
    Enrolment
    710

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionAtazanavir; Atazanavir/Ritonavir; Tenofovir/Emtricitabine; Lopinavir/ritonavir
    PhasePhase 3
    Registry statusCompleted

  • Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy

    NCT00234962 · start 2002-08

    Registered record
    Registry ID
    NCT00234962
    Conditions
    HIV Infection
    Interventions
    Lopinavir/Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2002-08
    Completion
    2007-02
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionLopinavir/Ritonavir
    PhasePhase 4
    Registry statusTerminated

  • Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV

    NCT00035932 · start 2001-11

    Registered record
    Registry ID
    NCT00035932
    Conditions
    HIV Infections
    Interventions
    Atazanavir + ritonavir + tenofovir + nucleoside; Atazanavir + saquinavir + tenofovir + nucleoside; Lopinavir/ritonavir + tenofovir + nucleoside
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-11
    Completion
    2009-03
    Enrolment
    571

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAtazanavir + ritonavir + tenofovir + nucleoside; Atazanavir + saquinavir + tenofovir + nucleoside; Lopinavir/ritonavir + tenofovir + nucleoside
    PhasePhase 3
    Registry statusCompleted

  • Long-term Effectiveness and Safety in Hepatitis-co-infected Patients

    NCT01153269 · start 2001-05

    Registered record
    Registry ID
    NCT01153269
    Conditions
    Human Immunodeficiency Virus-Infection
    Interventions
    Lopinavir/Ritonavir (Kaletra)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2001-05
    Completion
    2010-11
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus-Infection
    InterventionLopinavir/Ritonavir (Kaletra)
    PhaseNot recorded
    Registry statusCompleted